NovMetaPharma Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2014	FY 2013
Period Ending	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013
Revenue	1,295	1,068
Revenue Growth (YoY)	21.36%	-
Cost of Revenue	683.23	534.68
Gross Profit	612.26	532.83
Selling, General & Admin	614.01	395.98
Research & Development	59.73	34.91
Other Operating Expenses	15.11	20.64
Operating Expenses	735.64	484.82
Operating Income	-123.38	48.01
Interest & Investment Income	9.3	0.6
Currency Exchange Gain (Loss)	24.15	-29.08
Other Non Operating Income (Expenses)	80.65	0.08
EBT Excluding Unusual Items	-9.27	19.62
Gain (Loss) on Sale of Investments	417.3	-
Pretax Income	408.03	19.62
Net Income	408.03	19.62
Net Income to Common	408.03	19.62
Net Income Growth	1979.47%	-
Shares Outstanding (Basic)	3	3
Shares Outstanding (Diluted)	3	3
Shares Change (YoY)	21.30%	-
EPS (Basic)	120.00	7.00
EPS (Diluted)	120.00	7.00
EPS Growth	1614.28%	-
Free Cash Flow	-263.81	164.26
Free Cash Flow Per Share	-77.58	58.60
Gross Margin	47.26%	49.91%
Operating Margin	-9.52%	4.50%
Profit Margin	31.50%	1.84%
Free Cash Flow Margin	-20.36%	15.39%
EBITDA	-75.2	79.9
EBITDA Margin	-5.80%	7.48%
D&A For EBITDA	48.18	31.88
EBIT	-123.38	48.01
EBIT Margin	-9.52%	4.50%
Advertising Expenses	29.58	3

Source: S&P Global Market Intelligence. Standard template. Financial Sources.